Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
261780
vs
K
KOSPI 200
Over the past 12 months, CHA Vaccine Research Institute has underperformed KOSPI 200, delivering a return of +44% compared to KOSPI 200's +116% growth.
Stocks Performance
261780 vs KOSPI 200
Performance Gap
261780 vs KOSPI 200
Performance By Year
261780 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CHA Vaccine Research Institute
Glance View
CHA Vaccine Research Institute is a South Korean biotechnology company focused on researching and developing vaccine candidates, including vaccines for infectious diseases and other immune-based therapies. In plain terms, it tries to turn lab research into vaccine products that can be tested, licensed, and eventually used by patients or public-health buyers. Its main customers and partners are usually pharmaceutical companies, hospitals, research institutions, and other biotech groups that need vaccine know-how, preclinical research, or clinical development support. The company can make money by licensing its vaccine technology, signing research collaboration deals, and earning payments tied to development progress or commercialization rights. What makes this business different is that it sits at the research-heavy front end of the vaccine value chain. Instead of mass-manufacturing and selling finished shots like a large vaccine maker, it focuses on discovering and advancing vaccine science, then sharing that value with partners who handle later-stage development, manufacturing, and distribution.